Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.

Khan HY, Ge J, Nagasaka M, Aboukameel A, Mpilla G, Muqbil I, Szlaczky M, Chaker M, Baloglu E, Landesman Y, Mohammad RM, Azmi AS, Sukari A.

Int J Mol Sci. 2019 Dec 29;21(1). pii: E237. doi: 10.3390/ijms21010237.

2.

PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors.

Mpilla G, Aboukameel A, Muqbil I, Kim S, Beydoun R, Philip PA, Mohammad RM, Kamgar M, Shidham V, Senapedis W, Baloglu E, Li J, Dyson G, Xue Y, El-Rayes B, Azmi AS.

Cancers (Basel). 2019 Nov 29;11(12). pii: E1902. doi: 10.3390/cancers11121902.

3.

Perceptions Pertaining to Clinical Depression in Karachi, Pakistan.

Nisar M, Mohammad RM, Fatima S, Shaikh PR, Rehman M.

Cureus. 2019 Jul 7;11(7):e5094. doi: 10.7759/cureus.5094.

4.

Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.

Muqbil I, Chaker M, Aboukameel A, Mohammad RM, Azmi AS, Ramchandren R.

Heliyon. 2019 Aug 31;5(8):e02290. doi: 10.1016/j.heliyon.2019.e02290. eCollection 2019 Aug.

5.

DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma.

Azmi AS, Li Y, Aboukameel A, Muqbil I, Philip PA, Mohammad RM.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1101. doi: 10.3390/cancers11081101.

6.

Influence of Dietary Intake on Sleeping Patterns of Medical Students.

Nisar M, Mohammad RM, Arshad A, Hashmi I, Yousuf SM, Baig S.

Cureus. 2019 Feb 20;11(2):e4106. doi: 10.7759/cureus.4106.

7.

Evaluation of cationic channel TRPV2 as a novel biomarker and therapeutic target in Leukemia-Implications concerning the resolution of pulmonary inflammation.

Siveen KS, Prabhu KS, Parray AS, Merhi M, Arredouani A, Chikri M, Uddin S, Dermime S, Mohammad RM, Steinhoff M, Janahi IA, Azizi F.

Sci Rep. 2019 Feb 7;9(1):1554. doi: 10.1038/s41598-018-37469-8.

8.

Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.

Teslow EA, Mitrea C, Bao B, Mohammad RM, Polin LA, Dyson G, Purrington KS, Bollig-Fischer A.

Mol Oncol. 2019 Apr;13(4):894-908. doi: 10.1002/1878-0261.12444. Epub 2019 Mar 1.

9.

Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells

Krishnankutty R, Iskandarani A, Therachiyil L, Uddin S, Azizi F, Kulinski M, Bhat AA, Mohammad RM.

Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3501-3509.

10.

Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.

Ennkaa A, Shaath N, Salam A, Mohammad RM.

Turk J Gastroenterol. 2018 Sep;29(5):549-554. doi: 10.5152/tjg.2018.17707.

11.

Nuclear Export Inhibition for Pancreatic Cancer Therapy.

Muqbil I, Azmi AS, Mohammad RM.

Cancers (Basel). 2018 May 7;10(5). pii: E138. doi: 10.3390/cancers10050138. Review.

12.

Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration.

Azmi AS, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman MG, Philip PA, Mohammad RM.

Oncotarget. 2017 Jul 17;8(47):82144-82155. doi: 10.18632/oncotarget.19285. eCollection 2017 Oct 10.

13.

Dysregulated expression of SKP2 and its role in hematological malignancies.

Kulinski M, Achkar IW, Haris M, Dermime S, Mohammad RM, Uddin S.

Leuk Lymphoma. 2018 May;59(5):1051-1063. doi: 10.1080/10428194.2017.1359740. Epub 2017 Aug 10. Review.

PMID:
28797197
14.

Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells.

Prabhu KS, Siveen KS, Kuttikrishnan S, Iskandarani A, Tsakou M, Achkar IW, Therachiyil L, Krishnankutty R, Parray A, Kulinski M, Merhi M, Dermime S, Mohammad RM, Uddin S.

PLoS One. 2017 Jul 13;12(7):e0180895. doi: 10.1371/journal.pone.0180895. eCollection 2017.

15.

Molecular genetic analysis of consanguineous families with primary microcephaly identified pathogenic variants in the ASPM gene.

Khan MA, Windpassinger C, Ali MZ, Zubair M, Gul H, Abbas S, Khan S, Badar M, Mohammad RM, Nawaz Z.

J Genet. 2017 Jun;96(2):383-387.

16.

Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

Small GTPases. 2019 Sep;10(5):367-377. doi: 10.1080/21541248.2017.1329694. Epub 2017 Jun 23.

17.

Anticancer potential of sanguinarine for various human malignancies.

Achkar IW, Mraiche F, Mohammad RM, Uddin S.

Future Med Chem. 2017 Jun;9(9):933-950. doi: 10.4155/fmc-2017-0041. Epub 2017 Jun 21. Review.

PMID:
28636454
18.

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.

Ning C, Liang M, Liu S, Wang G, Edwards H, Xia Y, Polin L, Dyson G, Taub JW, Mohammad RM, Azmi AS, Zhao L, Ge Y.

Oncotarget. 2017 Jul 4;8(27):44295-44311. doi: 10.18632/oncotarget.17869.

19.

Potential therapeutic targets of Guggulsterone in cancer.

Bhat AA, Prabhu KS, Kuttikrishnan S, Krishnankutty R, Babu J, Mohammad RM, Uddin S.

Nutr Metab (Lond). 2017 Feb 28;14:23. doi: 10.1186/s12986-017-0180-8. eCollection 2017. Review.

20.

Targeting acute myeloid leukemia stem cell signaling by natural products.

Siveen KS, Uddin S, Mohammad RM.

Mol Cancer. 2017 Jan 30;16(1):13. doi: 10.1186/s12943-016-0571-x. Review.

21.

Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.

Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

Mol Cancer Ther. 2017 Jan;16(1):76-87. doi: 10.1158/1535-7163.MCT-16-0205. Epub 2016 Nov 15.

22.

Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges.

Siveen KS, Prabhu K, Krishnankutty R, Kuttikrishnan S, Tsakou M, Alali FQ, Dermime S, Mohammad RM, Uddin S.

Curr Vasc Pharmacol. 2017;15(4):339-351. doi: 10.2174/1570161115666170105124038. Review.

PMID:
28056756
23.

The Molecular Genetics of Autosomal Recessive Nonsyndromic Intellectual Disability: a Mutational Continuum and Future Recommendations.

Khan MA, Khan S, Windpassinger C, Badar M, Nawaz Z, Mohammad RM.

Ann Hum Genet. 2016 Nov;80(6):342-368. doi: 10.1111/ahg.12176. Review.

24.

Targeting Cancer at the Nuclear Pore.

Azmi AS, Mohammad RM.

J Clin Oncol. 2016 Dec;34(34):4180-4182. Epub 2016 Oct 23. No abstract available.

PMID:
27863200
25.

Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.

Muqbil I, Aboukameel A, Elloul S, Carlson R, Senapedis W, Baloglu E, Kauffman M, Shacham S, Bhutani D, Zonder J, Azmi AS, Mohammad RM.

Cancer Lett. 2016 Dec 28;383(2):309-317. doi: 10.1016/j.canlet.2016.09.016. Epub 2016 Sep 28.

26.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

27.

Cholesterol Depletion Alters Cardiomyocyte Subcellular Signaling and Increases Contractility.

Haque MZ, McIntosh VJ, Abou Samra AB, Mohammad RM, Lasley RD.

PLoS One. 2016 Jul 21;11(7):e0154151. doi: 10.1371/journal.pone.0154151. eCollection 2016.

28.

The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.

Diab M, Muqbil I, Mohammad RM, Azmi AS, Philip PA.

J Clin Med. 2016 Jun 16;5(6). pii: E59. doi: 10.3390/jcm5060059. Review.

29.

Measurement of 1,5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay.

Halama A, Kulinski M, Kader SA, Satheesh NJ, Abou-Samra AB, Suhre K, Mohammad RM.

J Transl Med. 2016 May 18;14(1):140. doi: 10.1186/s12967-016-0897-6.

30.

Therapeutic Potential of Resveratrol in Lymphoid Malignancies.

Khan OS, Bhat AA, Krishnankutty R, Mohammad RM, Uddin S.

Nutr Cancer. 2016;68(3):365-73. doi: 10.1080/01635581.2016.1152386. Epub 2016 Mar 30. Review.

PMID:
27028800
31.

Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.

Iskandarani A, Bhat AA, Siveen KS, Prabhu KS, Kuttikrishnan S, Khan MA, Krishnankutty R, Kulinski M, Nasr RR, Mohammad RM, Uddin S.

J Transl Med. 2016 Mar 9;14:69. doi: 10.1186/s12967-016-0823-y.

32.

F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS.

Semin Cancer Biol. 2016 Feb;36:95-104. doi: 10.1016/j.semcancer.2016.01.002. Epub 2016 Jan 21. Review.

33.

Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.

Muqbil I, Mohammad RM.

Ann Transl Med. 2015 Nov;3(20):312. doi: 10.3978/j.issn.2305-5839.2015.09.15. No abstract available.

34.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

35.

Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.

Azmi AS, Muqbil I, Wu J, Aboukameel A, Senapedis W, Baloglu E, Bollig-Fischer A, Dyson G, Kauffman M, Landesman Y, Shacham S, Philip PA, Mohammad RM.

Sci Rep. 2015 Nov 5;5:16077. doi: 10.1038/srep16077.

36.

Involvement of F-BOX proteins in progression and development of human malignancies.

Uddin S, Bhat AA, Krishnankutty R, Mir F, Kulinski M, Mohammad RM.

Semin Cancer Biol. 2016 Feb;36:18-32. doi: 10.1016/j.semcancer.2015.09.008. Epub 2015 Sep 26. Review.

PMID:
26410033
38.

Role of leptin and leptin receptors in hematological malignancies.

Uddin S, Mohammad RM.

Leuk Lymphoma. 2016;57(1):10-6. doi: 10.3109/10428194.2015.1063145. Epub 2015 Jul 7. Review.

PMID:
26077362
39.

Broad targeting of resistance to apoptosis in cancer.

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS.

Semin Cancer Biol. 2015 Dec;35 Suppl:S78-S103. doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28. Review.

40.

p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?

Azmi AS, Mohammad RM.

Future Med Chem. 2015;7(1):5-7. doi: 10.4155/fmc.14.144. No abstract available.

PMID:
25582328
41.

Erratum to: Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity.

Sahin K, Orhan C, Tuzcu M, Muqbil I, Sahin N, Gencoglu H, Guler O, Padhye SB, Sarkar FH, Mohammad RM.

Biol Trace Elem Res. 2015 Mar;164(1):162-3. doi: 10.1007/s12011-014-0198-y. No abstract available.

PMID:
25488703
42.

Snail nuclear transport: the gateways regulating epithelial-to-mesenchymal transition?

Muqbil I, Wu J, Aboukameel A, Mohammad RM, Azmi AS.

Semin Cancer Biol. 2014 Aug;27:39-45. doi: 10.1016/j.semcancer.2014.06.003. Epub 2014 Jun 17. Review.

43.

Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.

Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra AB, Mohammad RM.

Oncotarget. 2014 Jun 15;5(11):3444-54.

44.

Rectifying cancer drug discovery through network pharmacology.

Azmi AS, Mohammad RM.

Future Med Chem. 2014 Apr;6(5):529-39. doi: 10.4155/fmc.14.6.

PMID:
24649956
45.

Regulation of KRAS-PAK4 axis by microRNAs in cancer.

Choudhry ZS, Tripathi V, Sutton M, Bao B, Mohammad RM, Azmi AS.

Curr Pharm Des. 2014;20(33):5275-8. Review.

PMID:
24479809
46.

Comparative in vivo evaluations of curcumin and its analog difluorinated curcumin against cisplatin-induced nephrotoxicity.

Sahin K, Orhan C, Tuzcu M, Muqbil I, Sahin N, Gencoglu H, Guler O, Padhye SB, Sarkar FH, Mohammad RM.

Biol Trace Elem Res. 2014 Feb;157(2):156-63. doi: 10.1007/s12011-014-9886-x. Epub 2014 Jan 12. Erratum in: Biol Trace Elem Res. 2015 Mar;164(1):162-3.

PMID:
24415068
47.

Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy.

Muqbil I, Bao GW, El-Kharraj R, Shah M, Mohammad RM, Sarkar FH, Azmi AS.

J Stem Cell Res Ther. 2012 Dec 16;Suppl 7(5). pii: 10413.

48.

Association of PPARγ2 gene variant Pro12Ala polymorphism with hypertension and obesity in the aboriginal Qatari population known for being consanguineous.

Bener A, Darwish S, Al-Hamaq AO, Mohammad RM, Yousafzai MT.

Appl Clin Genet. 2013 Oct 24;6:103-11. doi: 10.2147/TACG.S49875. eCollection 2013.

49.

A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.

Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, Gulappa T, Cierpicki T, Owens S, Zhang T, Sun D, Stuckey JA, Mohammad RM, Nikolovska-Coleska Z.

Mol Cancer Ther. 2014 Mar;13(3):565-75. doi: 10.1158/1535-7163.MCT-12-0767. Epub 2013 Sep 9.

Supplemental Content

Loading ...
Support Center